Population Pharmacokinetics and Pharmacodynamics of Zidovudine in HIV‐Infected Infants and Children
Authors:
- 1 February 2003
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 43 (2) , 133-140
Abstract
The purpose of this study was to assess the population pharmacokinetics (PK) and pharmacodynamics (PD) of zidovudine (ZDV) in infants and children. This evaluation includes 394 subjects who participated in Pediatric AIDS Clinical Trials Group (PACTG) Study 152 and received either ZDV alone or in combination with didanosine. The most significant PK covariate was age, with infants < 2 years of age having reduced size‐adjusted clearance. ZDV exposure was weakly related to maximal reduction in immune complex‐dissociated (ICD) p24 antigen but not to reduction at 6 months. Mild chronic anemia occurred in 7.6% of subjects with ZDV average concentration < 1.3 μM (350 ng/mL) versus in 23.4% subjects with higher ZDV concentrations (p < 0.001). There was a direct linear relationship between hemoglobin and ZDV levels. It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity.Keywords
This publication has 23 references indexed in Scilit:
- Virologic and Immunologic Response to Nucleoside Reverse‐Transcriptase Inhibitor Therapy among Human Immunodeficiency Virus–Infected Infants and ChildrenThe Journal of Infectious Diseases, 1999
- Concentration-controlled zidovudine therapy*Clinical Pharmacology & Therapeutics, 1998
- Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected ChildrenNew England Journal of Medicine, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.British Journal of Clinical Pharmacology, 1994
- The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082)American Journal of Obstetrics and Gynecology, 1993
- Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virusThe Journal of Pediatrics, 1993
- Radioimmunoassay for Retrovir, An Anti-Human Immunodeficiency Virus DrugJournal of Immunoassay, 1989
- Azidothymidine Steady-State Pharmacokinetics in Patients with AIDS and AIDS-Related ComplexThe Journal of Infectious Diseases, 1989
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981